Adaptimmune Therapeutics PLCNASDAQ:ADAP
- LAST PRICE1.0100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.2200/ 40
- Ask / Lots1.2300/ 15
- Open / Previous Close1.0500 / 1.0100
- Day Range
- 52 Week Range
- Volume3,923,317
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADAP |
|---|---|---|
| 09:32 ET | 6491 | 1.055 |
| 09:34 ET | 53002 | 1.055 |
| 09:36 ET | 23014 | 1.045 |
| 09:39 ET | 13960 | 1.033 |
| 09:41 ET | 38924 | 1.03 |
| 09:45 ET | 200 | 1.02 |
| 09:48 ET | 3055 | 1.02 |
| 09:50 ET | 2005 | 1.01 |
| 09:52 ET | 600 | 1.01 |
| 09:54 ET | 600 | 1.015 |
| 09:56 ET | 15531 | 1 |
| 09:57 ET | 20018 | 1.01 |
| 09:59 ET | 11810 | 1.005 |
| 10:01 ET | 1300 | 1.01 |
| 10:03 ET | 12986 | 1.005 |
| 10:06 ET | 221 | 1.005 |
| 10:08 ET | 218 | 1.0085 |
| 10:10 ET | 1700 | 1.01 |
| 10:12 ET | 500 | 1.005 |
| 10:15 ET | 100 | 1.005 |
| 10:17 ET | 700 | 1 |
| 10:19 ET | 500 | 1 |
| 10:21 ET | 1600 | 1.005 |
| 10:24 ET | 300 | 1 |
| 10:26 ET | 1300 | 1 |
| 10:28 ET | 1900 | 1 |
| 10:30 ET | 17719 | 1.02 |
| 10:32 ET | 100 | 1.02 |
| 10:33 ET | 10474 | 1.015 |
| 10:35 ET | 10625 | 1.015 |
| 10:42 ET | 100 | 1.015 |
| 10:44 ET | 5389 | 1.005 |
| 10:46 ET | 1699 | 1.005 |
| 10:48 ET | 2822 | 1.0022 |
| 10:50 ET | 3400 | 1.005 |
| 10:51 ET | 2900 | 1.01 |
| 10:53 ET | 10798 | 1.01 |
| 10:55 ET | 950 | 1.01 |
| 10:57 ET | 1100 | 1.01 |
| 11:00 ET | 10168 | 1.01 |
| 11:02 ET | 1500 | 1.005 |
| 11:04 ET | 151 | 1.005 |
| 11:08 ET | 1502 | 1 |
| 11:09 ET | 700 | 1 |
| 11:11 ET | 5600 | 1 |
| 11:13 ET | 2200 | 1 |
| 11:15 ET | 800 | 1 |
| 11:18 ET | 400 | 1 |
| 11:20 ET | 300 | 1 |
| 11:22 ET | 5625 | 1 |
| 11:24 ET | 400 | 1.005 |
| 11:26 ET | 100 | 1 |
| 11:27 ET | 200 | 1 |
| 11:29 ET | 300 | 1 |
| 11:31 ET | 350 | 1.0089 |
| 11:33 ET | 7758 | 1 |
| 11:36 ET | 3100 | 1.0083 |
| 11:38 ET | 1200 | 1 |
| 11:40 ET | 600 | 1 |
| 11:42 ET | 200 | 1 |
| 11:44 ET | 400 | 1 |
| 11:45 ET | 100 | 1.005 |
| 11:47 ET | 800 | 1.0083 |
| 11:49 ET | 400 | 1 |
| 11:58 ET | 600 | 1 |
| 12:02 ET | 100 | 1.005 |
| 12:07 ET | 5685 | 1.01 |
| 12:09 ET | 200 | 1.005 |
| 12:12 ET | 3046 | 1.009 |
| 12:14 ET | 200 | 1 |
| 12:16 ET | 50101 | 1.019 |
| 12:18 ET | 4600 | 1.025 |
| 12:20 ET | 100 | 1.025 |
| 12:21 ET | 744 | 1.025 |
| 12:23 ET | 5443 | 1.02 |
| 12:25 ET | 7722 | 1.02 |
| 12:27 ET | 1865 | 1.015 |
| 12:30 ET | 3200 | 1.01 |
| 12:32 ET | 1100 | 1.015 |
| 12:34 ET | 3600 | 1.01 |
| 12:36 ET | 1000 | 1.01 |
| 12:38 ET | 500 | 1.01 |
| 12:39 ET | 1900 | 1.01 |
| 12:41 ET | 200 | 1.015 |
| 12:43 ET | 400 | 1.01 |
| 12:45 ET | 800 | 1.01 |
| 12:48 ET | 800 | 1.01 |
| 12:50 ET | 3939 | 1.015 |
| 12:52 ET | 1200 | 1.015 |
| 12:54 ET | 40294 | 1.015 |
| 12:56 ET | 2000 | 1.01 |
| 12:57 ET | 4300 | 1.015 |
| 12:59 ET | 2800 | 1.01 |
| 01:01 ET | 781 | 1.015 |
| 01:03 ET | 17707 | 1.005 |
| 01:06 ET | 9350 | 1.009 |
| 01:08 ET | 1600 | 1.01 |
| 01:10 ET | 300 | 1.01 |
| 01:12 ET | 200 | 1.01 |
| 01:14 ET | 200 | 1.01 |
| 01:15 ET | 700 | 1.01 |
| 01:19 ET | 500 | 1.01 |
| 01:21 ET | 100 | 1.01 |
| 01:24 ET | 400 | 1.01 |
| 01:26 ET | 300 | 1 |
| 01:28 ET | 16562 | 1 |
| 01:30 ET | 2864 | 1.015 |
| 01:32 ET | 596 | 1.015 |
| 01:33 ET | 200 | 1.015 |
| 01:35 ET | 588 | 1.015 |
| 01:37 ET | 100 | 1.015 |
| 01:39 ET | 200 | 1.015 |
| 01:42 ET | 2200 | 1.02 |
| 01:44 ET | 1080 | 1.015 |
| 01:46 ET | 300 | 1.01 |
| 01:48 ET | 710 | 1.0152 |
| 01:50 ET | 1000 | 1.015 |
| 01:51 ET | 300 | 1.01 |
| 01:53 ET | 100 | 1.01 |
| 01:55 ET | 200 | 1.015 |
| 01:57 ET | 400 | 1.015 |
| 02:00 ET | 100 | 1.01 |
| 02:02 ET | 100 | 1.015 |
| 02:04 ET | 200 | 1.01 |
| 02:06 ET | 200 | 1.01 |
| 02:08 ET | 14000 | 1.015 |
| 02:09 ET | 200 | 1.015 |
| 02:11 ET | 15434 | 1.015 |
| 02:13 ET | 300 | 1.015 |
| 02:15 ET | 1200 | 1.015 |
| 02:18 ET | 600 | 1.015 |
| 02:20 ET | 600 | 1.01 |
| 02:22 ET | 700 | 1.015 |
| 02:24 ET | 2500 | 1.01 |
| 02:26 ET | 5169 | 1.0152 |
| 02:27 ET | 5600 | 1.015 |
| 02:29 ET | 9078 | 1.015 |
| 02:31 ET | 300 | 1.015 |
| 02:33 ET | 2166 | 1.01 |
| 02:36 ET | 1700 | 1.01 |
| 02:38 ET | 1000 | 1.01 |
| 02:40 ET | 500 | 1.01 |
| 02:42 ET | 300 | 1.015 |
| 02:44 ET | 407 | 1.01 |
| 02:45 ET | 9095 | 1.015 |
| 02:47 ET | 2400 | 1.015 |
| 02:49 ET | 2686 | 1.015 |
| 02:51 ET | 500 | 1.015 |
| 02:54 ET | 5900 | 1.015 |
| 02:56 ET | 100 | 1.015 |
| 02:58 ET | 85796 | 1.015 |
| 03:00 ET | 21600 | 1.015 |
| 03:02 ET | 7004 | 1.0116 |
| 03:03 ET | 1200 | 1.015 |
| 03:05 ET | 1238 | 1.0183 |
| 03:07 ET | 1230 | 1.015 |
| 03:09 ET | 1200 | 1.015 |
| 03:12 ET | 6700 | 1.01 |
| 03:14 ET | 1500 | 1.01 |
| 03:16 ET | 500 | 1.01 |
| 03:18 ET | 774 | 1.01 |
| 03:20 ET | 500 | 1.01 |
| 03:21 ET | 9500 | 1.01 |
| 03:23 ET | 500 | 1.0175 |
| 03:25 ET | 100 | 1.01 |
| 03:27 ET | 500 | 1.01 |
| 03:30 ET | 400 | 1.01 |
| 03:32 ET | 1180 | 1.01 |
| 03:34 ET | 7578 | 1.02 |
| 03:36 ET | 200 | 1.015 |
| 03:38 ET | 6700 | 1.01 |
| 03:39 ET | 779 | 1.01 |
| 03:41 ET | 700 | 1.015 |
| 03:43 ET | 500 | 1.015 |
| 03:45 ET | 1600 | 1.01 |
| 03:48 ET | 60850 | 1.01 |
| 03:50 ET | 8700 | 1.01 |
| 03:52 ET | 4236 | 1.01 |
| 03:54 ET | 3013 | 1.01 |
| 03:56 ET | 5635 | 1.0117 |
| 03:57 ET | 6870 | 1.01 |
| 03:59 ET | 11315 | 1.01 |
Today
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications, from 7 hours ago by Dow Jones
7 hours ago by Dow JonesDJ Adaptimmune Therapeutics Initiated at Sector Outperform by Scotiabank, from 12 hours ago by Dow Jones
12 hours ago by Dow Jones
May 17, 2024
DJ Adaptimmune Therapeutics Is Maintained at Buy by Mizuho, from 7:41AM ET on Friday May 17, 2024 by Dow Jones
7:41AM ET on Friday May 17, 2024 by Dow Jones
May 15, 2024
Adaptimmune Reports Q1 2024 Financial and Business Updates, from 7:32AM ET on Wednesday May 15, 2024 by Dow Jones
7:32AM ET on Wednesday May 15, 2024 by Dow JonesAdaptimmune Secures up to $125 Million Debt Financing with Hercules Capital, from 7:01AM ET on Wednesday May 15, 2024 by Dow Jones
7:01AM ET on Wednesday May 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adaptimmune Therapeutics PLC | 258.1M | -1.4x | --- |
MacroGenics Inc | 259.3M | -11.3x | --- |
Innate Pharma SA | 224.7M | -27.1x | --- |
Poseida Therapeutics Inc | 279.2M | -2.5x | --- |
AVITA Medical Inc | 227.3M | -5.3x | --- |
Codexis Inc | 225.1M | -3.6x | --- |
Company Information
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
Contact Information
- Headquarters
- 60 Jubilee Avenue, Milton ParkABINGDON, United Kingdom OX14 4RX
- Phone
- 123-543-0000
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- David Mott
- Chief Executive Officer, Director
- Adrian Rawcliffe
- Chief Financial Officer
- Gavin Wood
- Chief Operating Officer
- William Bertrand
- Chief Scientific Officer
- Joanna Brewer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $258.1M |
|---|---|
Revenue (TTM) | $18.4M |
Shares Outstanding | 255.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.31 |
EPS | $-0.73 |
Book Value | $0.17 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 14.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -918.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
